The effect of pentoxifylline on cerebral blood flow (CBF) was studied with the intravenous 133Xe clearance technique in eleven patients with chronic cerebrovascular disease. Pentoxifylline was administered orally at a dose of 1200 mg/day over a period of 30 days (eight patients) or by intravenous infusion of 100 ml saline containing 400 mg of the drug in 1 hour (three patients). CBF was measured before and after pharmacological treatment. CBF was found to be significantly increased by both acute and chronic administration of pentoxifylline.
Get full access to this article
View all access options for this article.
References
1.
AschkarDDorazilESiglH (1972) Zur klinischen Anwendung des neuen Vasotherapeuticum BL 191 bei peripheren und zerebralen Durchblutungsstorungen. Therapiewoche22, 3646.
2.
BuchananNMoodleyG P (1977) The effect of pentoxifylline on human erythrocyte adenosine triphosphate. IRCS Med. Sci., 5, 43.
3.
DintenfassL (1976) Effect of 3,7-dimethyl-1-(5-oxohexyl)-xanthine (Trental, BL 191) on the blood viscosity factors in vitro. Pharmatherapeutica1, 290.
4.
FellnerRSimonA (1972) Untersuchungen uber die durchblutungsverbessernde Wirkung von BL 191 auf die Chorioidea des menschlichen auges. Klin. Monatsbl. Augenheilkd., 161, 439.
5.
HartmannA (1980) Effect of pentoxifylline on regional blood flow in patients with cerebrovascular disorders. In: Capri Conference, Capri, October 1980. (In press).
6.
HeidrichHPaeprerMBarckowDSchartlM (1976) The effect of pentoxifylline on central and peripheral haemodynamics – an experimental clinical study. Z. Kardiol, 65, 385.
7.
HeidrichHOttM (1974) Vasodilatentien und Blutviskositat. Herz/Kreisl., 6, 542.
8.
HeinsiusEFlammP (1973) Ophthalmologische Erfahrungen mit dem neuen Xanthinkorper BL 191. Med. Klin., 68, 1540.
9.
HergerR (1972) Erfahrungen mit dem neuen Vasotherapeuticum Trental in der dermatologischen Fachpraxis. Fortschr. Med., 90, 865.
10.
HessHFrankeIJauchM (1973) Medikamentose Verbesserung der Fliesseigenschaften des Blutes. Ein wirksames Prinzip zur Behandlung von arteriellen Durchblutungsstorungen. Fortschr. Med., 91, 743.
11.
HirschHWoscheeG J (1971) Erfahrungen mit einen Xanthinderivat bei zentralen und peripheren Durchblutungsstorungen. Ther. Ggw., 11, 1668.
12.
HuppertzM (1973) Clinical experience with a new xanthine derivative in the treatment of acute impairment of hearing and in deafness. Therapiewoche51, 5008.
13.
JiingerH (1974) Klinische Erfahrungen mit Pentoxifyllin (BL 191) bei der Ulcus-cruris-Behandlung. Wien. Med. Wochenschr., 9, 134.
14.
KoppenhagenKWenigH GMullerK (1977a) Measurement of cerebral blood flow following intravenous administration of pentoxifylline (‘Trental’). Current Medical Research and Opinion4, 521.
15.
KoppenhagenKWenigH GMullerK (1977b) The effect of pentoxifylline (‘Trental’) on cerebral blood flow: a double-blind study. Current Medical Research and Opinion4, 681.
16.
MansfeldH G (1972) Therapieerfahrungen mit einen neuen Xanthinderivat bei peripheren und zentralen Durchblutungsstorungen. Dtsch. Med. J., 23, 49.
SprietAMcruretA (1973) Un critere clinlque objectif dans la therapeutique de l'insiffisance circolatoire chronique. Gaz. Med. Fr., 80, 3657.
19.
StefanovichV (1975) Effect of pentoxifylline on energy phosphates in rat's erythrocytes. Res. Commun. Chem. Pathol. Pharmacol., 10, 747.
20.
StörmerBKleinschmidtKLooseDKremerK (1977) Rheological changes in the blood of patients with chronic arterial occlusive disease after the administration of vasoactive drug. Current Medical Research and Opinion4, 223.
21.
VölkerDHaemorheological investigations in patients with vascular disease undergoing treatment with pentoxifylline. Pharmatherapeutica1, 154.
